What smart money is saying about Insmed Incorporated
4 funds in our archive have pitched Insmed Incorporated — most recently Baron Health Care Fund in June 2026.
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Get an email when a fund writes about it
Position history
Between Q4 2024 and Q3 2026, 6 fund letters reported a position in Insmed Incorporated — 1 opened or added to the position, 2 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 0 | 0 |
| Q2 2026 | 4 | 0 | 2 | 1 |
| Q1 2026 | 1 | 1 | 0 | 1 |
| Q3 2025 | 0 | 0 | 0 | 1 |
| Q4 2024 | 0 | 0 | 0 | 1 |
Fund activity · 6 positions · 3 moves
- HoldsRhenman Healthcare Equity L/SAugust 2026
“The best contributors for the month were all biopharma names, including Iovance, Insmed and Merck.”
Insmed Incorporated - June 2026
“Our biggest detractors in Q2 were Insmed, ROBLOX and Insulet.”
Insmed Incorporated - June 2026
“We trimmed the position during the quarter.”
Insmed Incorporated - June 2026
“Top detractors from performance for the quarter Contribution to Return (%) Insmed Incorporated (0.97) Intuitive Surgical, Inc. (0.50) Gilead Sciences, Inc. (0.34) AstraZeneca PLC (0.25) IDEXX Laboratories, Inc. (0.13) Insmed Incorporated is a biotechnology company with three lead pulmonology assets that we believe can collectively generate more than $8 billion in peak sales.”
Insmed Incorporated - June 2026
“Insmed is a commercial-stage biotechnology company focused on pulmonary diseases. BRINSUPRI® continued its rapid launch, with robust patient uptake and encouraging third-party data. While Q1 sales came in modestly below elevated investor expectations, reflecting concerns around discontinuation rates, continuation on therapy and typical early-year seasonality, the underlying launch trajectory remains encouraging. We continue to view BRINSUPRI® as a significant long-term opportunity. Our due diligence suggests the therapy remains well tolerated and is on track to achieve blockbuster-level sales. We trimmed the position during the quarter.”
Insmed Incorporated - March 2026
“Insmed Inc., a developer of therapies for patients with serious and rare diseases, dropped -6%. The launch of Brinsupri is well ahead of expectations. That medication received FDA approval last summer as the first treatment for non-cystic fibrosis bronchiectasis, a chronic lung disease. Management also noted that Arikayce sales were below the Street. That prescription antibiotic is used to treat refractory Mycobacterium avium complex lung disease. In our view, Brunsupri is their primary driver, with expectations of $1 billion in sales for 2026. We added to the position.”
Insmed Incorporated
Also mentioned · 2
These funds discuss Insmed Incorporated — as a competitor, benchmark or comparable — without disclosing a position in it.
- June 2026
“The largest contributors to relative returns were CrowdStrike, Vertiv, Snowflake, Broadcom and not owning Insmed.”
Insmed Incorporated - MentionedTimesSquare U.S. Mid Cap GrowthJune 2026
“Insmed Inc. develops and commercializes therapies for patients with serious and rare diseases.”
Insmed Incorporated
Fund coverage · 4 theses
- Baron Health Care FundJune 2026
Insmed has a pulmonology pipeline with multi-billion-dollar peak sales potential, led by Brinsupri and once-daily TPIP.
Read the full thesis - Artisan Global Discovery StrategyMarch 2026
Insmed is a pulmonary-focused biotech with durable ARIKAYCE revenue and a promising Brinsupri launch that could drive a meaningful profit cycle.
Read the full thesis - Orbis Global EquitySeptember 2025
Insmed is poised for sustained profitability following the FDA approval of its bronchiectasis treatment, brensocatib, while also advancing its promising pipeline in respiratory diseases.
Read the full thesis - Baron Health Care FundDecember 2024
Insmed Incorporated is expected to generate over $8 billion in peak sales from its lead drugs, including Brensocatib, which shows promise for treating non-cystic fibrosis bronchiectasis.
Read the full thesis
Read every full thesis on Insmed Incorporated
Unlock all 4 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→